GSK's Tykerb "Little More" to Offer
The future of GSK’s Tykerb (lapatinib) in the breast cancer market is unclear, after the combination of Tykerb and Herceptin in the large Phase III trial.
The future of GSK’s Tykerb (lapatinib) in the breast cancer market is unclear, after the combination of Tykerb and Herceptin in the large Phase III trial, ALTTO, showed no statistical superiority over Herceptin alone for improving disease-free survival, says research and consulting firm GlobalData.
“Tykerb has failed to establish itself as a strong competitor in the HER2 positive market, and its use in the adjuvant setting was the only way it could gain a decent share of the breast cancer therapeutics market after Roche launched Perjeta and Kadcyla,” said GlobalData analyst Jamie Mallinson, Ph.D.
This failure indicates that there is “little more to expect from Tykerb”. GlobalData believes that neither GSK nor Novartias, who bought GSK’s oncology portfolio in April, will spend significant efforts in marketing the drug further.
Mallinson added: “For now, the pharmaceutical industry keenly awaits the results of the adjuvant Perjeta clinical trial, APHINITY, with preliminary DFS data expected in 2016.”
Perjeta was approved for use in the neoadjuvant setting by the FDA in 2013.
Reshema Kemps-Polanco: Taking Risks for Greater Reward
May 14th 2025Reshema Kemps-Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of the Year, uses the lessons she learned from her family to bring out the best in her teams.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.
